28 Aug 2026 Punjab Khabarnama Bureau : For decades, statins have been the foundation of cholesterol management. But the battle against LDL, or “bad” cholesterol, is entering a new phase, with newer medicines targeting different biological pathways and offering additional options for patients who need greater LDL reduction or cannot tolerate standard treatment.
Statins Remain the Foundation
Statins continue to play a central role in preventing heart attacks and strokes by lowering LDL cholesterol. However, updated 2026 US cholesterol guidelines place greater emphasis on earlier treatment, lower LDL targets and reducing cumulative exposure to plaque-forming cholesterol over a person’s lifetime.
For patients who do not reach their treatment goals with statins alone, doctors can consider adding non-statin therapies depending on cardiovascular risk and individual circumstances.
PCSK9 Inhibitors Change the Game
One of the most important developments has been the targeting of PCSK9, a protein produced by the liver.
PCSK9 reduces the number of LDL receptors available to remove cholesterol from the bloodstream. Blocking PCSK9 allows more receptors to remain active, helping the liver clear LDL more efficiently.
PCSK9-targeting treatments can produce substantial LDL reductions and are particularly important for people at high cardiovascular risk who need additional treatment beyond statins and ezetimibe.
Inclisiran Offers Less Frequent Dosing
Inclisiran takes a different approach to the same PCSK9 pathway.
It is a small-interfering RNA treatment designed to reduce the liver’s production of PCSK9. Its longer dosing interval could make it an attractive option for some patients who struggle with taking medicines regularly.
The broader shift is toward therapies that can complement existing cholesterol medicines rather than simply replacing statins.
Bempedoic Acid for Statin-Intolerant Patients
Another important option is bempedoic acid, particularly for people who cannot tolerate adequate doses of statins.
Unlike statins, bempedoic acid acts primarily in the liver and can be used alone or alongside other lipid-lowering medicines. Evidence and expert guidance increasingly support its role in patients with statin intolerance or those who remain above their LDL goals despite treatment.
Ezetimibe Remains an Important Partner
Ezetimibe works differently from statins by reducing cholesterol absorption in the intestine.
It is often used alongside a statin when additional LDL lowering is required. Combining therapies that work through different mechanisms can provide substantially greater LDL reduction than relying on a single medicine.
The Goal Is Getting LDL Lower Earlier
The latest thinking in cholesterol management is increasingly focused not just on treating very high cholesterol later in life, but on reducing long-term exposure to LDL cholesterol.
The 2026 ACC/AHA guideline introduces updated risk assessment and cholesterol targets, while also highlighting measurements such as lipoprotein(a) and apolipoprotein B to improve risk assessment in selected patients.
A More Personalised Approach
The future of cholesterol management is unlikely to involve one medicine for everyone.
Doctors increasingly have multiple options and can choose treatment according to cardiovascular risk, LDL levels, previous heart disease, familial cholesterol disorders, statin tolerance, cost and patient preferences.
For some patients, a statin may be sufficient. Others may require combinations involving ezetimibe, bempedoic acid or PCSK9-targeting therapies.